Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 4/20 | 0.53 |
| ▸ | ERCC5 | P28715 | 3/20 | 0.53 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.53 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1885513 | 0.74 | ERCC5 (0.46) | FEN1ERCC5ERCC1ERCC4GRM1 | |
| SCHEMBL1892197 | 0.74 | ERCC5 (0.46) | FEN1ERCC5ERCC1ERCC4GRM1 | |
| SCHEMBL1890340 | 0.72 | ERCC5 (0.46) | FEN1ERCC5ERCC1ERCC4MEN1 | |
| SCHEMBL1888920 | 0.70 | FEN1 (0.43) | FEN1ERCC5ERCC1ERCC4GRM1 | |
| SCHEMBL1886589 | 0.70 | FEN1 (1.00) | FEN1ERCC5ERCC1ERCC4GRM1 | |
| SCHEMBL1890099 | 0.68 | MAPT (0.57) | FEN1ERCC5ERCC1ERCC4ALDH1A1 | |
| SCHEMBL10741605 | 0.64 | BRD4 (0.38) | FEN1ERCC5ERCC1ERCC4GRM1 | |
| SCHEMBL15391338 | 0.64 | PDPK1 (0.47) | FEN1ERCC5ERCC1ERCC4GRM1 | |
| SCHEMBL9398179 | 0.61 | ADRA1D (0.51) | FEN1ERCC5ERCC1ERCC4ADORA2B | |
| SCHEMBL15939806 | 0.60 | GRM1 (1.00) | GRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947691-B2 | Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof | ATHERSYS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | ATHERSYS, INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287465-A1 | Cyclic N-Hydroxy Imides as Inhibitors of Flap Endonuclease and Uses Thereof | FEN1, UNG, POLH | FEN1 1/4885ERCC5 73/4885ERCC1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.